ActiveMax® Mouse VEGF164 (VE4-M4216) is expressed from human 293 cells (HEK293). It contains AA Ala 27 - Arg 190 (Accession # AAB22253.1 ).
Predicted N-terminus: Ala 27
This protein carries no "tag".
The protein has a calculated MW of 19.3 kDa. The protein migrates as 23-25 kDa on a SDS-PAGE gel under reducing (R) condition due to different glycosylation.
Less than 1.0 EU per μg by the LAL method.
>95% as determined by SDS-PAGE.
>95% as determined by SEC-HPLC.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
No activity loss is observed after storage at:
- 4-8°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ActiveMax® Mouse VEGF164 on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
The purity of ActiveMax® Mouse VEGF164 (Cat.# VE4-M4216) was greater than 95% as determined by SEC-HPLC.
Immobilized ActiveMax® Mouse VEGF164 (Cat# VE4-M4216) at 2 μg/mL (100 μL/well) can bind VEGFR2 / R3-Fc with a linear range of 0.3-2.5 ng/mL.
Vascular endothelial growth factor A (VEGFA) is also known as Vascular permeability factor (VPF). VEGFA belongs to the PDGF/VEGF growth factor family. VEGFA is a glycosylated mitogen that specifically acts on endothelial cells and has various effects, including mediating increased vascular permeability, inducing angiogenesis, vasculogenesis and endothelial cell growth, promoting cell migration, and inhibiting apoptosis. Alternatively spliced transcript variants, encoding either freely secreted or cell-associated isoforms, have been characterized. VEGFA is produced by a group of three major isoforms as a result of alternative splicing and if any three isoforms are produced (VEGFA120, VEGFA164, and VEGFA188) then this will not result in vessel defects and death of the full VEGFA knockout in mice.
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.